Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro.
Chemotherapy is a primary treatment for cancer, but its efficacy is often limited by the adverse effects of cytotoxic agents. Targeted drug delivery may reduce the non-specific toxicity of chemotherapy by selectively directing anticancer drugs to tumor cells. MUC1 protein is an attractive target for...
Main Authors: | Yan Hu, Jinhong Duan, Qimin Zhan, Fengdan Wang, Xin Lu, Xian-Da Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3284512?pdf=render |
Similar Items
-
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
by: Zhaoyi Li, et al.
Published: (2019-01-01) -
Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
by: Chenchen Yu, et al.
Published: (2011-01-01) -
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive <it>Breast</it> Cancer Cells <it>in Vitro</it>
by: Liu Zhe, et al.
Published: (2012-07-01) -
A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers
by: Lianyuan Yu, et al.
Published: (2015-01-01) -
Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics
by: Haibin Wu, et al.
Published: (2017-01-01)